Cell Therapy
& Bispecifics
US Focus Meeting 2026
📍 Hilton Austin, 500 E 4th St, Austin, TX 78701
🗓️ March 6 - 7, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Cell Therapy & Bispecifics Focus Meeting 2026, to be held at on March 6 - 7, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Cell Therapy & Bispecifics research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Cell Therapy & Bispecifics US Focus Meeting 2026:
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
Thanks to Our Supporters
Gold
Silver
Additional Support provided by Adaptive Biotech
Agenda & Faculty
March 6, 2026 | Day 1
9:05 AM
Keynote 1; CAR T-Cell Therapy for Solid and Brain Tumors
GK
Giedre Krenciute, PHD
St. Jude Children's Research Hospital, Memphis, TN
Session I: Aggressive B-Cell Lymphoma
Moderated by:
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
9:35 PM
Real-world Outcomes with CAR-T in LBCL
MH
Mehdi Hamadani, MD
Medical College of Wisconsin, Wauwatosa, WI
9:55 PM
Real-world Outcomes with Bispecifics in LBCL
BH
Brian Hill, MD
Cleveland Clinic, Cleveland, OH
10:15 PM
Immune Reconstitution After IEC Therapy in Lymphoma
RS
Roni Shouval, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
Session II: Updates in Myeloma
Moderated by:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
11:15 AM
Updates on Approved CAR-T-Cells and Real-world Data
Krina Patel, MD
MD Anderson Cancer Center, Houston, TX
11:35 AM
Updates on Approved Bispecifics and Real-world Data
Joshua Richter, MD
Icahn School of Medicine at Mount Sinai, New York, NY
11:55 AM
Treatment of Relapse After Bispecifics or CAR-T-Cells: Belantamb and Other Approaches
Andrew Yee, MD
Massachusetts General Hospital, Boston, MA
Session III: B-ALL and AML
Moderated by:
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
1:25 PM
CAR-T as Consolidation in Adult B-ALL
Ibrahim Aldoss, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
1:45 PM
CAR-T for T-ALL
Armin Ghobadi, MD
Washington University School of Medicine, St. Louis, MO
2:05 PM
How Do I Use CAR-T in Adult ALL
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
2:25 PM
CAR-T for AML. Progress and Pitfalls
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
Session IV: Indolent and Mantle Cell Lymphoma
Moderated by:
Lia Palomba, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
3:25 PM
Is Follicular Lymphoma Curable with CAR-T or Bispecifics?
Erin Mulvey, MD
Weill Cornell Medicine, New York, NY
3:45 PM
In Favor of CAR-T
Lia Palomba, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
3:55 PM
In Favor of Bispecifics
YW
Yucai Wang MD
Mayo Clinic, Rochester, MN
Fellow Abstract Review Session I
Moderated by:
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
4:25 PM
Germline Variants and Their Role in the Pathogenesis of IEC-HS
AL
Anath Lionel, MD
MD Anderson Cancer Center, Houston, TX
4:45 PM
Targeting B- and T-Cell Lymphomas with anti-CXCR5 CAR T-Cell Therapy
KC
Karan Chohan, MD
Mayo Clinic, Rochester, MN
March 7, 2026 | Day 2
9:05 AM
Keynote 2: Mechanisms and Treatment of Uncommon Toxicities After IEC Therapies
SP
Samir Parekh, MD
Icahn School of Medicine at Mount Sinai, New York, NY
Session V: Novel Approaches in Myeloma
Moderated by:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
9:35 AM
Novel Bispecific and Trispecific Antibody Therapies and Combinations for Myeloma
Diana Cirstea, MD
Massachusetts General Hospital, Boston, MA
9:55 AM
Novel CAR T-Cell Therapies for Myeloma Including Off-the-Shelf Allogeneic and In Vivo CARs
BP
Benjamin Puliafito, MD
Massachusetts General Hospital, Boston, MA
10:15 AM
Management of Toxicities for CAR T-Cells and Bispecifics in a Changing Landscape
Doris Hansen, MD
Moffitt Cancer Center, Tampa, FL
Session VI: CLL and T-ALL
Moderated by:
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
11:15 AM
CAR-T for CLL. Is There a Cure Fraction?
Javier Pinilla-Ibarz, MD
Moffitt Cancer Center, Tampa, FL
11:35 AM
Towards Chemo-free/Chemo-lite Strategy in Adult ALL
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
Session VII: Novel Approaches in Lymphoma
Moderated by:
Reem Karmali, MD
Northwestern University Feinberg School of Medicine, Chicago, IL
2:10 PM
When Should We Use Bispecifics in Follicular Lymphoma?
Reem Karmali, MD
Northwestern University Feinberg School of Medicine, Chicago, IL
2:30 PM
Novel CAR-T Therapies for LBCL
SD
Saurabh Dahiya, MD
Stanford Medicine, CA
2:50 PM
Novel CAR-T Targets for T-Cell Lymphomas
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
Session VIII: Transplant and CNS Lymphoma
Moderated by:
Sairah Ahmed, MD
MD Anderson Cancer Center, Houston, TX
3:50 PM
Non-relapse Mortality After IEC Therapy
AJ
Andrew Jallouk, MD
Vanderbilt University Medical Center, Nashville, TN
4:10 PM
In Favor of Transplant
NJ
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
4:20 PM
In Favor of No Transplant
ML
Marlise Luskin, MD
Dana-Farber Cancer Institute, Boston, MA
4:30 PM
In Favor of CAR-T
Sairah Ahmed, MD
MD Anderson Cancer Center, Houston, TX
4:40 PM
In Favor of Bispecifics
EB
Elizabeth Budde, MD
City of Hope, Duarte, CA
Alex Worthington
Project Manager
How long has Alex Worthington been in the business?
Alex Worthington has been with MD Education since 2024.
About Alex Worthington
As Project Manager, I work to ensure the Smooth running of events, assisting in the search process, outreach, organization, and the maintenance of any event. Having a Diverse Career background Working around the world, I pride myself on networking and creating positive relationships seamlessly with all attendees.
